TriLink BioTechnologies, Inc. (TriLink), a leading provider of custom nucleic acid-based compounds, announced it has signed a distribution agreement permitting tebu-bio SA (tebu) to sell its CleanAmp™ products. tebu-bio is a European based distributor that supplies over 750,000 reagents and lab services from manufacturers worldwide.

Mylan Inc. today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Schering Corporation and MSP Singapore Company in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg. This product is the generic version of Vytorin® Tablets, a cholesterol treatment.

Arcus Development Group Inc. (TSX VENTURE: ADG) (the "Company") announces that further to its news release of July 3, 2009, it has increased the size of its non-brokered flow-through private placement from 3,333,333 units to 4,650,000. The price of the units has been reduced from $0.15 to $0.13. Gross proceeds from the placement will be approximately $600,000. The exercise price of the associated flow-through warrants remains unchanged at $0.20.